Quick Answer
ANAPTYSBIO, INC reported R&D Expense of $88.80 million for fiscal year 2022.
ANAPTYSBIO, INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2022 | $88.80M | -9.8% |
| 2021 | $98.50M | +23.1% |
| 2020 | $80.03M | -19.4% |
| 2019 | $99.34M | +76.8% |
| 2018 | $56.20M | +90.9% |
| 2017 | $29.44M | +91.0% |
| 2016 | $15.42M | -10.9% |
| 2015 | $17.30M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $31.41M | -25.6% | -17.0% |
| June 30, 2025 | $37.82M | -9.9% | -8.1% |
| March 31, 2025 | $41.18M | +11.2% | -2.4% |
| September 30, 2024 | $42.21M | +36.7% | +0.5% |
| June 30, 2024 | $42.00M | +27.6% | +13.4% |
| March 31, 2024 | $37.04M | +6.0% | +20.0% |
| September 30, 2023 | $30.88M | +39.9% | -6.2% |
| June 30, 2023 | $32.92M | +57.9% | -5.8% |
- ANAPTYSBIO, INC showed a decrease of -9.8% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2022 period, ANAPTYSBIO, INC’s r&d expense has grown by 413.2% (from $17.30 million to $88.80 million).
- The most recent figure is from ANAPTYSBIO, INC’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 1, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: